Dr. Felix Berger
Professor of Pediatrics
Clinic of Congenital Heart Disease and Pediatric Cardiology
Deutsches Herzzentrum Berlin and Charité – Universitätsmedizin Berlin
Augustenburger Platz 1
13353 Berlin, Germany
Prof. Felix Berger, MD
Dr. Berger received his accreditation as a physician from the Christian-Albrechts University in 1986 and his MD from the University of Berlin in 1991 and his PhD from the University of Zurich, Switzerland in 2003. He trained in pediatric medicine and pediatric at Dept. of Pediatric Cardiology in Kiel from 1986-1988 finishing as a Pediatric Cardiology Clinical Fellow at the Deutsches Herzzentrum Berlin. From 1988-2001 he was a member of the pediatric cardiology faculty at the University of Berlin and directed the Cardiac Catheterization Laboratory at the Deutsches Herzzentrum Berlin from 1993 -2001. In 2001 he moved to the Children´s Hospital of the University of Zurich Switzerland as Director of Invasive and Interventional Pediatric Cardiology. In 2004 he moved back to Berlin as a Full Professor to act as Director of the Clinics of Congenital Heart Disease and Pediatric Cardiology at the Deutsches Herzzentrum Berlin and Charité – Universitaetsmedizin Berlin. Nationally and internationally he is a member of the German Society of Pediatric Cardiology and Cardiology, Swiss Society of Pediatric Cardiology and Cardiology, Association for European Pediatric Cardiologists, European Society of Cardiology, and Russian Scientific Society of Interventional Radiology and Endovascular Surgery. From 2010 – 2012 Dr. Berger has been President of the German Society of Pediatric Cardiology. Dr. Berger is an interventional cardiologist with clinical and investigative interests related to image guidance, congenital/valvular heart disease interventions, clinical trials, and developing innovative forms of treatment. He has many collaborators in interventional cardiology, cardiac imaging, imaging sciences, and congenital cardiac surgery. Among his interests in interventional cardiology he is also clinically and scientifically recognized for the management of adults with congenital heart disease, patients suffering from pulmonary arterial hypertension in combination with CHD, and intensive care medicine of patients suffering from CHD.